Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $22.33 USD
Change Today 0.00 / 0.00%
Volume 135.0K
BPMC On Other Exchanges
As of 8:10 PM 10/5/15 All times are local (Market data is delayed by at least 15 minutes).

blueprint medicines corp (BPMC) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/18/15 - $37.17
52 Week Low
04/30/15 - $18.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

blueprint medicines corp (BPMC) Related Businessweek News

No Related Businessweek News Found

blueprint medicines corp (BPMC) Details

Blueprint Medicines Corporation, a biopharmaceutical company, focuses on the development of the highly selective kinase inhibitors for genomically defined cancer subsets. The company’s lead drug candidates include BLU-285, which targets KIT Exon 17 and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants for patients with systemic mastocytosis, a myeloproliferative disorder of the mast cells, and defined subsets of patients with gastrointestinal stromal tumor, as well as targets the KIT D816V mutation; and BLU-554, an orally available, potent, selective, and irreversible inhibitor, which targets FGFR4. It is also developing a drug candidate to target RET, a receptor tyrosine kinase that can becomes abnormally activated when a portion of the gene that encodes RET is joined to part of another gene; and RET resistant mutants that would arise from treatment with first generation therapies, as well as a program that targets rare genetic diseases. The company has a research, development, and commercialization agreement with Alexion Pharma Holding to research, develop, and commercialize drug candidates for an undisclosed activated kinase target, which is the cause of a rare genetic disease. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is based in Cambridge, Massachusetts.

59 Employees
Last Reported Date: 04/30/15
Founded in 2008

blueprint medicines corp (BPMC) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $311.2K
Co-Founder, Director, Member of Nominating & ...
Total Annual Compensation: --
Chief Scientific Officer
Total Annual Compensation: $520.0K
Compensation as of Fiscal Year 2014.

blueprint medicines corp (BPMC) Key Developments

Blueprint Medicines Receives FDA Orphan Drug Designation for Novel Drug Candidate for Treatment of Hepatocellular Carcinoma

Blueprint Medicines announced that the U.S. Food and Drug Administration has granted orphan drug designation to its novel drug candidate BLU-554 for the treatment of hepatocellular carcinoma (HCC). BLU-554, an exquisitely selective inhibitor of fibroblast growth factor receptor 4 (FGFR4), is currently being evaluated in a Phase 1 clinical trial in patients with advanced HCC and cholangiocarcinoma. Aberrantly activated signaling of FGFR4 may be a key driver in up to 30% of HCC patients, according to an analysis by Blueprint Medicines, and BLU-554 has been shown to have significant anti-tumor activity in preclinical models of HCC driven by aberrant FGFR4 signaling.

Blueprint Medicines Receives FDA Authorization to Advance Novel Drug Candidate into Clinical Trial for Systemic Mastocytosis

Blueprint Medicines announced that the U.S. Food and Drug Administration (FDA) accepted the company's Investigational New Drug (IND) application to begin a Phase 1 clinical trial of BLU-285 in patients with advanced systemic mastocytosis (SM), a disorder of the mast cells. BLU-285 is a potent and highly selective inhibitor of the KIT D816V mutant, the primary driver of disease in more than 94% of SM patients. SM is characterized by the abnormal accumulation of mast cells. In patients with advanced forms of the disease, mast cells accumulate in organs, such as the bone marrow, intestines, spleen and liver, compromising organ function. There are no approved targeted therapies for SM patients with KIT D816V-driven disease. In this Phase 1 trial, Blueprint Medicines plans to enroll approximately 60 patients with advanced SM, which includes aggressive SM with associated hematological non-mast cell disorders (SM-AHNMD) and mast cell leukemia (MCL), and other relapsed or refractory myeloid malignancies at multiple sites in Europe and the United States. The trial will test the safety and tolerability of escalating doses of BLU-285, with the goal of establishing a maximum tolerated dose (MTD), or a recommended dose if the MTD is not achieved. Additional study objectives include assessing early signs of biological activity using disease-specific biomarkers and clinical efficacy as measured by response rate and patient-reported outcomes.

Blueprint Medicines Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Announces Executive Changes

Blueprint Medicines reported earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported collaboration revenues were $2.7 million for the second quarter of 2015. This revenue reflects reimbursement from Alexion for work conducted in the second quarter by Blueprint Medicines under the collaboration, as well as a portion of the $15.0 million upfront payment and $1.8 million milestone payment, which will be amortized over the period of the research term. Net loss was $13.0 million or $0.81 per basic and diluted share in the second quarter, compared to net loss of $8.3 million or $6.99 per basic and diluted share for the same period in 2014. For the six months, the company reported collaboration revenues of $3.33 million. Net loss was $24.552 million against $15.314 million a year ago. The company announced the resignation of Kyle Kuvalanka, Chief Business Officer, who will depart in mid-September. Michael Landsittel, Senior Director of Finance at Blueprint Medicines, will assume the responsibilities of interim Principal Accounting and Financial Officer and will report directly to Mr. Albers.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BPMC:US $22.33 USD 0.00

BPMC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BPMC.
View Industry Companies

Industry Analysis


Industry Average

Valuation BPMC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 114.3x
Price/Book 3.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 120.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BLUEPRINT MEDICINES CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at